India releases doses for the first treatment for Corona after granting emergency use permission

Indian Defense Minister Rajnath Singh and Federal Minister of Health Dr. Harsh Vardan on Monday released the first batch of 2-deoxy-D-glucose (2-DG) anti-corona virus drug developed by the Defense Research and Development Organization, and the therapeutic application of the drug was developed by the Institute of Nuclear Medicine. And associated science in collaboration with Dr. Reddy Laboratories in Hyderabad.

Earlier this month, India's Superintendent of Medicines approved the oral medication for emergency use as an adjunctive treatment for moderate to severe Coronavirus patients, the approval for the drug came at a time when India is grappling with a record wave of the Coronavirus pandemic that has strained the structure. The healthcare infrastructure in the country is stretched to its limits.

According to a report by the Indian Times of India, the treatment has undergone full trials and conducted trials in 30 hospitals and on a large number of patients.

The drug comes in the form of a powder in a bag that is taken orally by dissolving it in water, it accumulates in the cells infected with the virus and prevents the growth of the virus by stopping the viral synthesis and production of energy Its selective accumulation in the cells infected with the virus makes this drug unique.

According to the report, the results of clinical trials showed that this drug helps in the speedy recovery of patients in the hospital and reduces dependence on additional oxygen, a higher percentage of patients treated with 2DG showed a negative transformation of RT-PCR in patients with Corona.

The ministry statement said that in the second phase trials (including the range of doses) conducted during the period from May to October 2020, the drug was found to be safe for Corona patients and showed a significant improvement in their recovery, adding that the second phase was conducted in six hospitals and the phase was conducted. The second B dosing range of clinical trials in 11 hospitals across the country, in November 2020, phase 3 trials were approved and continued from December to April on May 1, the drug was approved for use in emergencies.